Antony C. Mattessich - Feb 3, 2022 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
President and CEO
Signature
/s/ Donald Notman, Attorney-in-Fact for Antony C. Mattessich
Stock symbol
OCUL
Transactions as of
Feb 3, 2022
Transactions value $
$0
Form type
4
Date filed
2/7/2022, 06:28 PM
Previous filing
Oct 28, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +187K +181.49% $0.00 290K Feb 3, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +560K $0.00 560K Feb 3, 2022 Common Stock 560K $5.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 Includes 186,750 shares of common stock of the Company underlying unvested RSUs.
F3 Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney